ClinicalTrials.gg
CompletedNCT01884337Updated Nov 29, 2019Results posted

Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

A Phase 4 interventional study of Apixaban in Anticoagulation, sponsored by Bristol-Myers Squibb. Completed at 20 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-29.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
557
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of this protocol is to evaluate the safety of Apixaban in prophylaxis of Venous Thromboembolism (VTE) in Indian patients undergoing elective total knee or hip replacement

02

Conditions studied

  • Anticoagulation
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Subjects undergoing elective total knee or hip replacement or a revision of at least one component of a total knee or hip replacement

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding
  • Known or suspected, acquired or bleeding or coagulation disorder in the subject or a first degree relative
  • Active bleeding or at high risk for bleeding.
  • Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days other than the elective knee/hip surgery
  • Active hepatobiliary disease
  • \<9 g/dL
  • count \<100,000/mm3
  • \<30 mL/min
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
557 participants (actual)

Study arms

  • Experimental
    Apixaban (2.5 mg)

    Apixaban 2.5 mg tablets by mouth twice daily, 12 days for TKR subjects or 35 days for THR subjects

    Drug: Apixaban

Interventions

  • Also known as: Eliquis, BMS-562247

06

What researchers measure

Primary outcomes

  1. Number of Participants With Composite of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding/Clinically Relevant Non-major Bleeding (CRNM) While Undergoing Elective TKR or THR at the End of Treatment + 2 Days

    TKR = Total knee replacement; THR = Total hip replacement. ISTH major bleeding is 1) Fatal or 2) Bleeding in a critical organ, such as brain, spine, eye, retroperitoneum, joint, heart sac, or skeletal muscle (and resulting in compartment syndrome), or 3) Bleeding that results in a fall of hemoglobin of 2 g/dL or more or transfusion of 2 units or more of packed red cells or whole blood within 24 hours. CRNM bleeding is bleeding that 1) Is clinically acute and overt 2) Does not satisfy criteria as a major bleed but requires medical intervention, such as a visit to a physician's office, emergency room, or urgent care center for epistaxis

    Time frame: 2 weeks + 2 days for TKR, 5 weeks + 2 days for THR

Secondary outcomes

  1. Number of Participants With Composite of Venous Thromboembolism (VTE)/All Cause Death at the End of Treatment + 2 Days

    VTE is the combination of deep vein thrombosis and non-fatal pulmonary embolism.

    Time frame: 2 weeks + 2 days for TKR, 5 weeks + 2 days for THR

07

Results

Posted Sep 9, 2019

Participant flow

This study was conducted in an Indian orthopedic population.

Treatment
Participant flow — Treatment
MilestoneTotal Knee Replacement (TKR)Total Hip Replacement (THR)
Started326172
Continuing into follow-up period324171
Completed322170
Not completed42
Withdrew: Adverse event22
Withdrew: Subj. request to discont. treatment20
Follow-up Period
Participant flow — Follow-up Period
MilestoneTotal Knee Replacement (TKR)Total Hip Replacement (THR)
Started324171
Completed323170
Not completed11
Withdrew: Lost to follow-up11

Outcome measures

PrimaryNumber of Participants With Composite of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding/Clinically Relevant Non-major Bleeding (CRNM) While Undergoing Elective TKR or THR at the End of Treatment + 2 Days

TKR = Total knee replacement; THR = Total hip replacement. ISTH major bleeding is 1) Fatal or 2) Bleeding in a critical organ, such as brain, spine, eye, retroperitoneum, joint, heart sac, or skeletal muscle (and resulting in compartment syndrome), or 3) Bleeding that results in a fall of hemoglobin of 2 g/dL or more or transfusion of 2 units or more of packed red cells or whole blood within 24 hours. CRNM bleeding is bleeding that 1) Is clinically acute and overt 2) Does not satisfy criteria as a major bleed but requires medical intervention, such as a visit to a physician's office, emergency room, or urgent care center for epistaxis

Time frame:
2 weeks + 2 days for TKR, 5 weeks + 2 days for THR
Reported as:
Count of participants · Participants
Number of Participants With Composite of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding/Clinically Relevant Non-major Bleeding (CRNM) While Undergoing Elective TKR or THR at the End of Treatment + 2 Days
ParticipantsTotal Knee Replacement (TKR)Total Hip Replacement (THR)
Major Bleeding00
Clinically Relevant Non-Major Bleeding01
Major or Clinically Relevant Non-Major Bleeding01
Any Bleeding01
SecondaryNumber of Participants With Composite of Venous Thromboembolism (VTE)/All Cause Death at the End of Treatment + 2 Days

VTE is the combination of deep vein thrombosis and non-fatal pulmonary embolism.

Time frame:
2 weeks + 2 days for TKR, 5 weeks + 2 days for THR
Reported as:
Count of participants · Participants
Number of Participants With Composite of Venous Thromboembolism (VTE)/All Cause Death at the End of Treatment + 2 Days
ParticipantsTotal Knee Replacement (TKR)Total Hip Replacement (THR)
Number of Participants With Composite of Venous Thromboembolism (VTE)/All Cause Death at the End of Treatment + 2 Days11

Adverse events

Collected over AEs are assessed from Day 1 through Day 42 +/- 2 days for Total Knee Replacement Participants; AEs are assessed from Day 1 through Day 65 +/-2 days for Total Hip Replacement Participants.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TOTAL KNEE REPLACEMENT (TKR)0/326 (0%)2/326 (0.6%)23/326 (7.1%)
TOTAL HIP REPLACEMENT (THR)0/172 (0%)0/172 (0%)6/172 (3.5%)
Most frequent serious events
Most frequent serious events
EventTOTAL KNEE REPLACEMENT (TKR)TOTAL HIP REPLACEMENT (THR)
AnaemiaBlood and lymphatic system disorders1/3260/172
VertigoEar and labyrinth disorders1/3260/172
Deep vein thrombosisVascular disorders1/3260/172
Most frequent other events
Most frequent other events
EventTOTAL KNEE REPLACEMENT (TKR)TOTAL HIP REPLACEMENT (THR)
Incision site painInjury, poisoning and procedural complications23/3266/172

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Total Knee Replacement (TKR)Total Hip Replacement (THR)Total
Mean60.7 ± 9.5941.7 ± 13.3054.1 ± 11.01
Sex: Female, Male
Sex: Female, Male(Participants)Total Knee Replacement (TKR)Total Hip Replacement (THR)Total
Female23753290
Male89119208
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Total Knee Replacement (TKR)Total Hip Replacement (THR)Total
Hispanic or Latino3912
Not Hispanic or Latino322163485
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Total Knee Replacement (TKR)Total Hip Replacement (THR)Total
American Indian or Alaska Native000
Asian326172498
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

20 sites
  • Local Institution
    Kozhikode, Kerala 673008, India
  • Local Institution
    Ahmedabad, 380015, India
  • Local Institution
    Ahmedabad, 380016, India
  • Local Institution
    Ahmedabad, 380060, India
  • Local Institution
    Alappuzha, 688005, India
  • Local Institution
    Aurangabad, 431003, India
  • Local Institution
    Bangalore, 560054, India
  • Local Institution
    Chandigarh, 160012, India
  • Local Institution
    Chennai, 600010, India
  • Local Institution
    Delhi, 110029, India
  • Local Institution
    Hyderabad, 500034, India
  • Local Institution
    Kerala, 695011, India
  • Local Institution
    Lucknow, 226003, India
  • Local Institution
    Mohali, 160062, India
  • Local Institution
    Mumbai, 400 022, India
  • Local Institution
    Nagpur, 440003, India
  • Local Institution
    Pune, 411001, India
  • Local Institution
    Pune, 411004, India
  • Local Institution
    Pune, 411005, India
  • Local Institution
    Pune, 411013, India
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Jun 2018, 38 months.

Results were first posted in Sep 2019, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2013
First posted
Jun 24, 2013
StartActual
Mar 24, 2015
Primary completionActual
Jun 4, 2018
CompletionActual
Jun 4, 2018
Results first posted
Sep 9, 2019
Last update
Nov 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01884337
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jun 24, 2013
Start date
Mar 24, 2015
Primary completion
Jun 4, 2018
Completion
Jun 4, 2018
Results posted
Sep 9, 2019
Last update
Nov 29, 2019

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion